Business Context and Reporting Period
Company: Daxor Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Daxor is a medical device manufacturer focused on the BVA-100 Blood Volume Analyzer, an instrument used to measure human blood volume for diagnosing conditions like heart failure and syncope. The company also operates Scientific Medical Systems, a subsidiary providing cryobanking services for blood and semen (Idant). The company relies heavily on investment income to offset operating losses while developing its core medical products.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Total Operating Revenues | $1,486,449 | $1,343,538 |
| Loss from Operations | $(5,436,671) | $(4,915,193) |
| Net Loss | $(785,531) | $(1,335,981) |
| Investment Income (Dividends + Gains) | $5,590,447 | $4,026,707 |
| Total Assets | $78,166,312 | $59,565,053 |
| Stockholders' Equity | $45,637,792 | $38,744,801 |
| Cash and Cash Equivalents | $2,838,927 | $93,003 |
| Short-Term Debt | $3,483,161 | $7,083,372 |
Note: The company's financial position is heavily supported by an investment portfolio valued at $66.97 million (fair market value) as of year-end 2006, which generated significant unrealized gains.
Material Changes vs. Prior Period
- Revenue Growth: Operating revenues increased 11% to $1.49 million, driven by a 40% increase in equipment and kit sales ($1.06 million vs. $0.75 million). Kit sales rose 35% following the correction of a Medicare reimbursement error regarding Volumex kits that had negatively impacted sales in 2005.
- Operating Loss: The operating loss widened to $5.44 million from $4.92 million, primarily due to increased Research and Development (R&D) expenses ($2.33 million vs. $2.15 million) and Selling, General, and Administrative (SG&A) expenses ($3.96 million vs. $3.54 million) as the company expanded its sales force and R&D facilities.
- Net Loss Improvement: Despite higher operating losses, the Net Loss decreased to $0.79 million from $1.34 million. This improvement was driven by a significant increase in investment gains on the sale of securities ($3.32 million vs. $1.52 million).
- Liquidity: Cash and cash equivalents surged to $2.84 million from $93,000, largely due to net cash provided by investing activities ($10.03 million) and a reduction in short-term margin debt.
- Asset Acquisition: In January 2007 (subsequent to year-end), the company purchased a 20,000 sq. ft. facility in Oak Ridge, Tennessee, for $775,000 to expand manufacturing and R&D.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management intends to increase marketing efforts to boost operating income, even if it initially results in increased losses. The company is pursuing UL and CE certifications for the BVA-100 to enable international marketing. The "Blood Optimization Program" (BOP) is being developed to combine blood volume analysis with autologous blood storage.
- SEC Investigation: The SEC has recommended bringing an action against the company and its CEO, Dr. Joseph Feldschuh, for alleged violations of Section 7(a) of the Investment Company Act of 1940. The company argues it is an operating company, not an investment company, and has agreed to indemnify the CEO for related expenses. The outcome remains uncertain.
- Key Risks:
- Customer Concentration: Three hospitals accounted for 35% of total consolidated sales in 2006.
- Single Supplier: The Volumex syringes are filled by a single FDA-approved manufacturer; cessation of this service would materially impact the business.
- Key Person Risk: The company is significantly dependent on Dr. Joseph Feldschuh for scientific expertise and investment management.
- Investment Policy: Approximately 91% of the investment portfolio consists of utility stocks, making it sensitive to interest rate changes.
- Internal Controls: The company previously identified material weaknesses in internal controls regarding financial reporting, leading to restatements of 2003-2005 data. Management hired a Controller and additional CPAs to address these issues and believes controls are now effective as of December 31, 2006.
Investor Verification Checklist
- SEC Enforcement Status: Verify the current status of the SEC recommendation regarding the Investment Company Act violation and any potential penalties.
- Investment Portfolio Valuation: Confirm the fair market value of the $67 million investment portfolio and the sustainability of the investment income strategy used to fund operations.
- Customer Concentration: Assess the stability of the three major hospital customers representing 35% of revenue.
- Medicare Reimbursement: Monitor the stability of Medicare reimbursement rates for the Volumex kits, which previously caused a sales disruption.
- Product Adoption: Track the conversion rate of trial agreements to permanent sales for the BVA-100 analyzer.